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Objectives The aim of this study was to assess the relationship between sex hormones and natriuretic peptide levels in
community-based adults.
Background Women have higher circulating natriuretic peptide concentrations than men, but the mechanisms for these sex-
related differences and the impact of hormone therapy are unclear. Experimental studies suggest that andro-
gens may suppress natriuretic peptide secretion.
Methods We measured N-terminal pro–B-type natriuretic peptide (NT-proBNP), total testosterone, and sex hormone–
binding globulin plasma levels in 4,056 men and women (mean age 40  9 years) from the Framingham Heart
Study Third-Generation cohort. Sex/hormone status was grouped as: 1) men; 2) post-menopausal women not
receiving hormone replacement therapy; 3) pre-menopausal women not receiving hormonal contraceptives;
4) post-menopausal women receiving hormone replacement therapy; and 5) pre-menopausal women receiving
hormonal contraceptives.
Results Circulating NT-proBNP levels were associated with sex/hormone status (overall p  0.0001). Men had lower NT-
proBNP levels than women of all menopause or hormone groups, and women receiving hormonal contraceptives
had higher NT-proBNP levels than women who were not receiving hormone therapy (all p  0.0001). These rela-
tionships remained significant after adjusting for age, body mass index, and cardiovascular risk factors. Across
sex/hormone status groups, free testosterone (FT) levels decreased and sex hormone–binding globulin levels
increased in tandem with increasing NT-proBNP levels. In sex-specific analyses, NT-proBNP levels decreased
across increasing quartiles of FT in men (p for trend 0.01) and women (p for trend 0.0001). Adjustment for
FT markedly attenuated the association between sex/hormone status and NT-proBNP concentrations.
Conclusions These findings suggest that lower levels of circulating androgens and the potentiating effect of exogenous fe-
male hormone therapy contribute to the higher circulating NT-proBNP concentrations in women. (J Am Coll
Cardiol 2011;58:618–26) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.042The importance of understanding the effects of sex and
hormone therapy on the cardiovascular system is under-
scored by the pronounced sex differences in the prevalence
of cardiovascular disease, the increase in cardiovascular
events in women following menopause, and concerns re-
garding the safety of hormone replacement therapy (HRT)
in post-menopausal women (1–3). Studies of circulating
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(NPs) (4–8), may provide a biological basis to better
See page 627
understand these sex-related differences in cardiovascular
risk. The NPs exert hormonal (vasodilation, natriuresis, and
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August 2, 2011:618–26 Sex/Hormone Status and Natriuretic Peptidesaldosterone and endothelin suppression) and autocrine/
paracrine (antihypertrophic, antifibrotic, and proangio-
genic) protective cardiovascular effects. Sex is one of the
strongest determinants of concentrations of circulating
B-type natriuretic peptide (BNP) or N-terminal pro–B-type
natriuretic peptide (NT-proBNP) in population-based
studies, with women having consistently higher circulating
levels than men (4–7). Nonetheless, the mechanisms underly-
ing the sex-based difference in circulating NPs have not been
established. Further, the effect of menstrual status, menopausal
status, or exogenous hormone therapy on plasma NP concen-
trations in women remains unclear (6,8–10).
Previous studies have suggested that sex hormones play an
important role in the regulation of NPs (11). On one hand,
estrogens have been shown to exert a stimulating effect on the
NP system (9,12) and are therefore postulated to mediate the
“NP excess” in women compared with men. On the other
hand, recent experimental (13,14) and cross-sectional human
data (8,15) suggest that androgens may exert an inhibitory
effect on the NP system, thus accounting for the lower NP
levels in men and potentially explaining the lack of cardiovas-
cular protection in men compared with women (8). However,
rior clinical studies of the influence of androgens on NPs were
imited to studying women (8,16) or children (15) and did not
ully characterize both endogenous (menstrual phase) and
xogenous (hormone therapy) variations. Further, previous
nvestigations did not include measures of insulin resistance,
hich is a potential confounder because hyperinsulinemia is
nown to be associated with both sex hormones (hyperandro-
enemia) and lowered NP concentrations (17–20).
We aimed to test the hypothesis that free testosterone
FT) is an important determinant of the relationship between
ex/hormone status and circulating NPs in adults from the
eneral population. Specifically, we hypothesized that higher
T levels in men compared with women and in women not
eceiving hormone therapy compared with those receiving
ormone therapy may be related to lower circulating concen-
rations of NPs. To achieve our aim, we measured levels of
estosterone and its primary binding protein, NP levels, and
nsulin measures in a large, community-based sample of
redominantly middle-aged adults grouped by sex, menstrual
tatus, and the presence or absence of hormone therapy.
ethods
tudy sample. The Framingham Heart Study (21) is a
ommunity-based cohort investigation that began in 1948
ith the recruitment of the Original Cohort, recruited a
econd generation in 1971 consisting of offspring of the
riginal Cohort and their spouses (Offspring Cohort), and
ost recently added a third generation in 2002 consisting of
hildren of the Offspring Cohort (Third-Generation Co-
ort). Participants of the youngest cohort (Third-
eneration Cohort), in whom plasma NT-proBNP con-
entrations were measured, were eligible for the current
tudy. Those with prevalent heart failure (prior diagnosis of meart failure based on Framing-
am criteria [22]), myocardial
nfarction, or serum creatinine
2 mg/dl were excluded from
he present investigation (n 
6). The index examinations
ook place during April 2002 to
uly 2005. All women had men-
trual histories recorded by
rained physicians using stan-
ardized questionnaires, includ-
ng details regarding reproduc-
ive history, first day of the last
enstrual period, frequency and
egularity of menstrual cycles,
nd current usage of any hor-
one therapy. Participants were
nstructed to bring all of their
urrent medications (taken within
month) with them to the ex-
mination, allowing verification by the examining physician.
nthropometric, blood pressure, and cardiovascular risk
actor data were obtained at the index visit using standard
rotocols. All participants provided written informed con-
ent, and protocols were approved by the Boston University
edical Center Institutional Review Board.
lassification of sex/hormone status. Menopause was
efined as the cessation of periods (in the absence of
regnancy) for at least 1 year because of naturally occurring
as opposed to surgical or medical) causes. Among post-
enopausal women, those receiving HRT were defined by
elf-reported current usage of female hormone therapy, as
ell as validation by direct assessment of all of the partici-
ants’ current medications by the examining physician.
mong pre-menopausal women, those receiving hormonal
ontraceptives (HC) were defined by self-reported current
sage of hormone-containing oral pills, injections, or im-
lants for birth control or medical indications, as well as
alidation by direct assessment of all of the participants’
urrent medications by the examining physician. Based on
hese definitions, sex/hormone status was classified into 5
ategories (Fig. 1):
• Men
• Post-menopausal women not receiving HRT
• Pre-menopausal women not receiving HC
• Post-menopausal women receiving HRT currently
• Pre-menopausal women receiving HC currently
In secondary analyses, we estimated the menstrual phase
follicular vs. luteal vs. midcycle) at the index visit among
re-menopausal women with regular ongoing menstrual
ycles (cycle lengths 28 to 30 days) who were not receiving
C. This determination was based on the fact that the
nterval from ovulation to menstruation (luteal phase) is
xed at 14 days, whereas the interval from the start of
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
FT  free testosterone
HC  hormonal
contraceptives
HOMA  homeostatic
model assessment
HRT  hormone
replacement therapy
IR  insulin resistance
NP  natriuretic peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
SHBG  sex
hormone–binding globulinenstruation to ovulation (follicular phase) can vary de-
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idely applied in similar studies (24–27). Thus, using the
ate of the examination, date of onset of the last menstrual
eriod, and menstrual cycle length (specifically ascertained
t the index examination), we derived the duration of the
ollicular phase in each regularly cycling woman, allowing 4
ays between the follicular and luteal phases for the mid-
ycle phase. The calculated durations were then used to
ssess whether NT-proBNP measurement on the date of
he index visit occurred in the follicular, midcycle, or luteal
hase of the menstrual cycle.
easurement of circulating NT-proBNP, testosterone,
nd SHBG. Venous blood was drawn under fasting con-
itions between 8:00 and 9:00 AM. Samples were immedi-
ately stored at 70°C and analyzed in batches in 2009,
allowing minimization of interassay variability and effects of
temporal drift in the laboratory measurements. Plasma
NT-proBNP levels were measured using a standard immu-
noassay (Roche Diagnostics, Indianapolis, Indiana), with a
measurement range of 5 to more than 35,000 ng/l and
intra-assay coefficient of variation of 2.7%. Serum total
testosterone concentrations were quantified using a vali-
dated liquid chromatography–tandem mass spectrometry
assay, with a lower detection limit of 2 ng/dl. Sex hormone–
binding globulin (SHBG) concentrations were measured
using an immunofluorometric assay (DELFIA-Wallac,
Inc., Turku, Finland). Total testosterone concentrations are
influenced by multiple factors, such as obesity in men and
oral contraceptive therapy in women, and may not reflect
Figure 1 Classification of Sex/Hormone Status
The flow chart illustrates the classification of sex/hormone status into 1) men; 2)
menopausal women not receiving hormonal contraceptives (HC); 4) current HRT us
in brackets.androgen activity. We thus calculated FT using the law ofmass action equation (28,29) and used FT in subsequent
analyses.
Measurement of insulin resistance. Insulin resistance
(IR) was calculated using the homeostatic model assessment
(HOMA) equation: HOMA-IR  (FPG  FPI)/22.5, for
which FPG  fasting plasma glucose (mmol/l) and FPI 
fasting plasma insulin (mU/l) measured by enzyme-linked
immunosorbent assay (Millipore Corporation, Billerica,
Massachusetts) (30).
Statistical analyses. The association between log NT-
proBNP and sex/hormone status was assessed using general
linear models followed by pairwise comparisons between
sex/hormone status groups with Bonferroni correction. The
model was adjusted for covariates known to influence
NT-proBNP concentrations (age, body mass index, systolic
blood pressure, diastolic blood pressure, serum creatinine,
and presence of antihypertensive medications, diabetes mel-
litus, and current smoking). We similarly assessed the
association of log FT and log SHBG with sex/hormone
status. Of a total of 2,165 women (Fig. 1), menopause status
was unclear or not due to natural causes in 186, HC usage
was unknown in 341, and FT/SHBG measurements or
clinical covariates were missing in a further 25, leaving 1,613
women in the final multivariable models for sex/hormone
status.
To assess the association between log NT-proBNP and
circulating androgens, we used sex-pooled and sex-specific
general linear models, in which the dependent variable was
log NT-proBNP and predictors were log FT or log SHBG
enopausal women not receiving hormone replacement therapy (HRT); 3) pre-
nd 5) current HC users. The age range of participants in each group is indicatedpost-m
ers; a(separately), hormone status (among women; categories 2 to
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(listed above). We tested for interaction between log FT or
log SHBG and hormone status among women and adjusted
models for HOMA-IR among participants without diabe-
tes. To further assess the association among sex/hormone
status, log NT-proBNP, and circulating androgen levels, we
analyzed multivariable models (sex pooled and in women
alone), in which the dependent variable was log NT-
proBNP and predictors sequentially included clinical cova-
riates (listed above), sex/hormone status groups (defined
above), and log FT. We assessed the beta coefficients for
each sex/hormone status group, compared with the referent
group of pre-menopausal women receiving HC, before and
after adding log FT to the model. We also compared the
type I sum of squares with the type III sum of squares for
the class variable sex/hormone status to assess the percent
variability in NT-proBNP levels due to sex/hormone status
before (type I sum of squares) and after (type III sum of
squares) the addition of log FT to the model, adjusting for
all other covariates. Of a total of 2,165 women and 1,891
men, FT measurements were available for 2,144 women and
1,880 men, whereas SHBG measurements were available
for 2,147 women and 1,880 men. Of these, there were no
missing clinical covariates (age, body mass index, systolic
blood pressure, diastolic blood pressure, serum creatinine,
antihypertensive medications, diabetes mellitus, and smok-
ing) in 2,123 women with FT measurements, 2,126 women
with SHBG measurements, and 1,871 men. In addition to
clinical covariates, HOMA-IR measurements were also
available for 1,857 women with FT measurements, 1,859
women with SHBG measurements, and 1,650 men.
In the subgroup of pre-menopausal women with regular
menstrual cycles in the absence of HC, we compared log
NT-proBNP concentrations among menstrual phases (follicular,
Baseline CharacteristicsTable 1 Baseline Characteristics
All
(N  4,056)
Age, yrs 40 9
Body mass index, kg/m2 26.9 5.6
Systolic blood pressure, mm Hg 117 14
Diastolic blood pressure, mm Hg 75 10
Serum creatinine, mg/dl 0.79 0.15
Hypertension 16
Antihypertensive medications 8
Diabetes mellitus 3
Smoking 17
NT-proBNP, ng/l 28.1 (14.1, 52.
Log NT-proBNP 3.3 1.0
FT, pg/ml 5.3 (2.1, 114.
Total testosterone, ng/dl 49.6 (23.7, 600
SHBG, nmol/l 55.1 (35.2, 96.
HOMA-IR 0.98 (0.70, 1.4
Values are mean  SD, %, or median (25th, 75th percentiles). To conv
convert total testosterone concentration to SI units (nmol/l), multiple
FT free testosterone; HOMA-IR homeostatic model assessment
SHBG  sex hormone–binding globulin.midcycle, and luteal) using general linear models with aBonferroni correction in pairwise comparisons among
phases. We similarly compared log FT and log SHBG
concentrations among menstrual phase groups. Models
were adjusted for covariates known to influence NT-
proBNP concentrations (listed above).
All analyses were performed using SAS software. Statis-
tical significance was determined at a p value of 0.05
(Bonferroni-adjusted significance level required p  0.05
[number of possible comparisons] in cases of multiple
comparisons).
Results
Baseline characteristics. Characteristics of the study sam-
ple (N  4,056; mean age 40 years) are shown in Table 1.
As expected in a predominantly middle-aged, community-based
sample, the prevalence of cardiovascular risk factors was
low, and the majority (83%) of women were pre-
menopausal (Fig. 1). Among pre-menopausal women,
23% (n  417) were currently receiving HC; among
post-menopausal women, 21% (n  40) were currently
receiving HRT. HRT consisted predominantly of oral
combination therapy with estrogen and progesterone
(n  34 [85%]). Of note, the age range of participants
as relatively narrow, even among post-menopausal
omen.
ssociation between sex/hormone status and circulating
T-proBNP levels. Log NT-proBNP was strongly asso-
iated with sex/hormone status (age-adjusted p  0.0001)
Fig. 2A), with the lowest concentrations in men and
ighest concentrations in pre-menopausal women receiving
C. These relationships remained unchanged after adjust-
ng for age, body mass index, systolic blood pressure,
iastolic blood pressure, serum creatinine, and presence of
Men
(n  1,891)
Women
(n  2,165)
40 9 40 9
28.0 4.7 26.0 6.1
121 13 113 14
78 9 73 9
0.90 0.13 0.70 0.11
21 12
10 7
4 2
18 16
16.2 (8.1, 28.8) 42.9 (25.7, 72.2)
2.7 0.9 3.7 0.8
119.0 (95.0, 152.0) 2.2 (1.4, 3.2)
617.7 (487.5, 786.1) 24.6 (17.7, 34.3)
37.0 (26.7, 50.2) 89.7 (58.7, 132.7)
1.01 (0.78, 1.66) 0.89 (0.65, 1.31)
oncentration to SI units (pmol/l), multiply values in pg/ml by 3.47; to
in ng/dl by 0.0347.
lin resistance; NT-proBNP N-terminal pro–B-type natriuretic peptide;6)
5)
.2)
1)
9)
ert FT c
valuesntihypertensive medications, diabetes mellitus, and smok-
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proBNP levels than women regardless of menopause status
or hormone therapy (Bonferroni-corrected p  0.0001).
Among pre-menopausal women, levels of NT-proBNP
were higher in those receiving HC (Bonferroni-corrected
p  0.0001). Among post-menopausal women, there was
o difference in circulating NT-proBNP levels between
urrent HRT users and nonusers (multivariable-adjusted
 0.39). In additional analyses including an interaction
erm between year of blood collection and sex, there was no
Figure 2 Association of Sex/Hormone Status With
Circulating NT-proBNP, Testosterone, and SHBG
(A) Columns and bars represent the age-adjusted least squares means and SE
of log N-terminal pro–B-type natriuretic peptide (NT-proBNP) by sex/hormone
status (1  men, 2  post-menopausal women not receiving HRT, 3  pre-
menopausal women not receiving HC, 4  post-menopausal HRT users, and
5  pre-menopausal HC users). The p value shown is for the association
between NT-proBNP and sex/hormone status overall; for pairwise comparisons
within sex/hormone status groups, please refer to the text. (B) Bivariate plot
showing the age-adjusted least squares means and SE of log free testosterone
(FT) (horizontal axis) and log NT-proBNP (vertical axis) in each sex/hormone
status group. (C) Bivariate plot showing the age-adjusted least squares means
and SE of log sex hormone–binding globulin (SHBG; horizontal axis) and log
NT-proBNP (vertical axis) in each sex/hormone status group. Abbreviations as
in Figure 1.vidence for an interaction.ssociation among circulating NT-proBNP, FT, and
HBG levels. As expected, men had the highest FT
oncentrations, whereas women receiving HC had the
owest FT and highest SHBG concentrations. Across sex/
ormone status groups, FT levels decreased and SHBG
evels increased in tandem with increasing NT-proBNP
evels (Figs. 2B and 2C).
In sex-stratified analyses, NT-proBNP levels were lower
n the highest quartiles of FT in both men (Fig. 3A) and
omen (Fig. 3B). Log NT-proBNP was inversely related to
og FT and directly related to log SHBG in both men and
omen (Table 2). After adjustments for age, body mass
ndex, systolic blood pressure, diastolic blood pressure,
erum creatinine, antihypertensive medications, diabetes,
nd smoking, the association between log NT-proBNP and
og FT was significant in women (p  0.0001) but not men
p 0.78). Each unit increase in log FT was associated with
20% decrease in NT-proBNP levels among women,
djusting for clinical covariates. Results were similar after
urther adjustments for HOMA-IR among participants
ithout diabetes. In both sexes, log NT-proBNP was
elated to log SHBG in multivariable analyses (p 0.0001).
ach unit increase in log SHBG was associated with a 19%
ncrease in NT-proBNP levels among men and a 40%
ncrease in NT-proBNP levels among women, adjusting for
linical covariates. There was no interaction between meno-
ause or hormone status and log FT or log SHBG.
Figure 3 Association Between
Circulating NT-proBNP and FT Levels
Least squares means and SE of log NT-proBNP are shown for each sex-specific
quartile (I to IV) of FT in men (triangles; A) and women (circles; B), respec-
tively. Abbreviations as in Figure 2.
0in wom
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August 2, 2011:618–26 Sex/Hormone Status and Natriuretic PeptidesIn the entire sample, sex/hormone status explained 38%
of the variability in NT-proBNP levels in multivariable
models adjusted for age, body mass index, systolic blood
pressure, diastolic blood pressure, serum creatinine, and
presence of antihypertensive medications, diabetes mellitus,
and smoking. This effect was larger than the contribution of
any other clinical covariate. The addition of log FT to
multivariable models adjusted for age, body size, and car-
diovascular risk factors led to attenuation of the differences
in log NT-proBNP among sex/hormone status groups
(Table 3). After log FT was added to the multivariable
model, clinical sex/hormone status only explained 1% of the
variability of NT-proBNP levels.
In women alone, the addition of log FT to multivariable
models similarly led to attenuation of the differences in log
NT-proBNP levels among menopause or hormone therapy
Association Among Circulating NT-proBNP, TestTable 2 Association Among Circulating NT-p
Association With Log NT-proBNP Beta
Entire sample (single variable)
Log FT 0.30
Log SHBG 0.23
Entire sample (multivariable)†
Log FT 0.03
Log SHBG 0.12
Nondiabetic patients only (multivariable)‡
Log FT 0.05
Log SHBG 0.13
*Beta coefficients represent the mean change in log NT-proBNP per 1
in men (both models), 2,144 in women (model containing log FT), and
index, systolic blood pressure, diastolic blood pressure, serum creatinin
in men (both models), 2,123 in women (model containing log FT), and
index, systolic blood pressure, diastolic blood pressure, serum creatini
(both models), 1,857 in women (model containing log FT), and 1,859
Abbreviations as in Table 1.
Multivariable Models Assessing the AssociationSex/Hormone Statu , Androgens, and NT-proBNTable 3 Mul ivariable Model Asse sing theSex/Hormone Status, Androgens, a
Association With Log NT-proBNP
M
Beta*
Entire sample (N  3,484)
Men 1.12 (0
Post-menopausal women without HRT 0.46 (0
Pre-menopausal women without HC 0.25 (0
Post-menopausal women with HRT 0.34 (0
Pre-menopausal women with HC Refere
Log FT —
Women only (n  1,613)
Post-menopausal women without HRT 0.35 (0
Pre-menopausal women without HC 0.22 (0
Post-menopausal women with HRT 0.25 (0
Pre-menopausal women with HC Refere
Log FT —
*Beta coefficients represent the mean difference in log NT-proBNP
pre-menopausal women receiving hormonal contraceptives (HC) (refe
adjusted for age, body mass index, systolic blood pressure, diastolic
mellitus, and smoking.
HC  hormonal contraceptives; HRT  hormone replacement therapy; othgroups (Table 3). Menopause and hormone status explained
14% of the variability in NT-proBNP levels in women and
in multivariable models adjusted for clinical covariates but
only 2% after log FT was added to the multivariable model.
Thus, the vast majority of the variability in NT-proBNP
due to menopause and hormone status in women appeared
to be attributable to differences in FT concentrations.
In analyses restricted to participants not receiving any
antihypertensive therapy, the associations among sex/hormone
status, NT-proBNP, and FT were unchanged (not shown).
Subgroup analysis by menstrual phase. Among 546 pre-
menopausal women with regular menstrual cycles in the
absence of HC (Table 4), NT-proBNP levels were lower in
the midcycle phase than in the follicular or luteal phase (p
.014 for midcycle vs. follicular phase; p  0.015 for
midcycle vs. luteal phase; Bonferroni-corrected p 0.05 for
one, and SHBGP, Testosterone, and SHBG
Men Women
p Value Beta* (SE) p Value
0.007 0.54 (0.05) 0.0001
0.0001 0.23 (0.02) 0.0001
0.78 0.47 (0.06) 0.0001
0.0001 0.25 (0.02) 0.0001
0.65 0.45 (0.06) 0.0001
0.0001 0.24 (0.02) 0.0001
erence in log FT or log SHBG; For single variable analyses, n  1,880
n women (model containing log SHBG). †Adjusted for age, body mass
hypertensive medications, diabetes mellitus, and smoking; n 1,871
n women (model containing log SHBG). ‡Adjusted for age, body mass
hypertensive medications, smoking, and HOMA-IR; n  1,650 in men
en (model containing log SHBG).
ngcentrationso iation Among
T-proBNP Concentrations
ithout FT Model With FT
p Value Beta* (SE) p Value
0.0001 0.51 (0.14) 0.0004
0.0001 0.35 (0.09) 0.0001
0.0001 0.14 (0.05) 0.008
0.015 0.24 (0.14) 0.083
Referent Referent Referent
— 0.27 (0.06) 0.0001
0.0001 0.17 (0.10) 0.073
0.0001 0.05 (0.06) 0.385
0.069 0.09 (0.14) 0.499
Referent Referent Referent
— 0.43 (0.07) 0.0001
corresponding sex/hormone status group compared with that in
up) or mean change in log NT-proBNP per 1 SD difference in log FT,
pressure, serum creatinine, antihypertensive medications, diabetesosterroBN
* (SE)
(0.11)
(0.03)
(0.11)
(0.03)
(0.12)
(0.03)
SD diff
2,147 i
e, anti
2,126 i
ne, antiAmoP Css
nd N
odel W
(SE)
.05)
.09)
.05)
.14)
nt
.09)
.05)
.14)
nt
in the
rent gro
blooder abbreviations as in Table 1.
tinine,
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trend toward higher FT levels in the midcycle phase
compared with that in the follicular or luteal phase (p 
0.045 for midcycle vs. follicular phase; p  0.099 for
midcycle vs. luteal phase). When log FT was added to
multivariable models, the association between menstrual
phase and log NT-proBNP became nonsignificant. There
was no association between SHBG levels and menstrual
phase.
Discussion
Principal findings. In a large sample of men and women
from the general community, sex and exogenous hormone
therapy were the largest determinants of variation in circu-
lating NT-proBNP levels. Men had lower plasma NT-
proBNP concentrations than women regardless of meno-
pause status or hormone therapy, whereas women receiving
HC had higher NT-proBNP concentrations than women
without hormone therapy. Among sex/hormone status
groups, men also had the highest FT and lowest SHBG
concentrations; conversely, women receiving HC had the
lowest FT and highest SHBG concentrations. In both
sexes, increasing NT-proBNP levels were related to de-
creasing FT and increasing SHBG concentrations. Ac-
counting for FT greatly attenuated the differences in circu-
lating NT-proBNP levels among sex/hormone status
groups, even after adjustments for known clinical covariates
and restricting analyses to women. These findings are
consistent with the hypothesis that androgens suppress
NT-proBNP and suggest that differences in FT concentra-
tions may largely explain the sex- and hormone-related
differences in circulating NPs.
Androgen regulation of NP concentrations. Several lines
of evidence suggest that testosterone may exert a suppressive
effect on the NP system and thus mediate a “BNP defi-
ciency” in men compared with women. In male rats,
orchiectomy produced marked increases in plasma NP
levels, and testosterone replacement restored NP concentra-
tions to baseline (14). In isolated perfused rat atria, testos-
terone suppressed volume-stimulated release of atrial NP
(13). However, contradictory results have also been reported
regarding the effect of testosterone on atrial NP gene
expression (31) and synthesis in cultured rat myocytes (32).
In clinical studies, inverse correlations between BNP and
FT levels have been observed in women in the Dallas Heart
Subgroup Analysis by Menstrual PhaseTable 4 Subgroup Analysis by Menstrual Phase
Multivariable-Adjusted*
Least-Squares Mean (SE)
Menstrual Phase
Follicular
(n  262)
Midcycle
(n  70)
Luteal
(n  214
Log NT-proBNP 3.71 (0.05) 3.45 (0.09) 3.71 (0.05
Log FT 0.91 (0.03) 1.05 (0.06) 0.93 (0.04
Log SHBG 4.33 (0.03) 4.38 (0.05) 4.33 (0.03
*Adjusted for age, body mass index, systolic blood pressure, diastolic blood pressure, serum crea
Abbreviations as in Table 1.Study (8) and in a small Japanese study (16). Androgenreceptor antagonism for prostate cancer has been associated
with large increases in levels of NT-proBNP (33). In male
children and adolescents, associations of decreasing FT,
increasing SHBG, and increasing NT-proBNP levels have
been noted (15).
Our findings extend prior observations to a large
community-based cohort of middle-aged men and women.
The demonstrated association between NT-proBNP and
androgens offers a potential unifying explanation for sex and
hormonal status-related differences in NP concentrations.
In men, low BNP concentrations may be related to the
suppressive effects of high concentrations of FT. A nonlin-
ear relationship with NT-proBNP at such high concentra-
tions of FT may explain the failure to detect a statistically
significant relationship between FT and NT-proBNP in
men following multivariable adjustment. In women, FT
concentrations are more than 50-fold lower than that in
men and are exquisitely sensitive to SHBG concentrations.
Estrogen regulation of NP concentrations. Previous
studies have also shown that estrogens may exert a stimu-
latory effect on the NP system (11). In female rats, pre-
treatment with estradiol and progesterone stimulated atrial
NP gene expression (31). In post-menopausal women,
administration of estrogens produced a rise in plasma levels
of BNP (9). A complex interplay of factors has been
postulated, in which estrogens modulate NP production via
known effects on the renin-angiotensin system (12).
Measurements of estradiol and estrone were not available
for the current study, limiting our conclusions regarding the
role of estrogens in mediating the observed difference in
NT-proBNP levels. However, according to the hypothesis
of a stimulatory effect of estrogens on NPs, we would have
expected post-menopausal women and men to have similar
NT-proBNP levels given their similar estrogen levels, yet
NT-proBNP concentrations were much higher in the for-
mer. Similarly, based on higher endogenous estrogens in
pre-menopausal than post-menopausal women, we would
have expected higher NT-proBNP levels in the former, but
levels were similar in the 2 groups. Lastly, given that the
midcycle (ovulatory) phase of the menstrual cycle is associ-
ated with higher estrogen levels compared with the follicular
or luteal phases, higher NT-proBNP levels would be ex-
pected midcycle; however, levels were paradoxically lower in
women at midcycle. Interestingly, each of the above obser-
vations can potentially be explained by variation in FT,
p Value
Follicular vs. Midcycle Follicular vs. Luteal Luteal vs. Midcycle
0.014 0.97 0.015
0.045 0.642 0.100
0.348 0.943 0.386
antihypertensive medications, diabetes mellitus, and smoking.)
)
)
)which is highest in men, comparable in pre- and post-
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than the follicular or luteal phase. These findings are
consistent with prior studies showing that circulating NT-
proBNP concentrations are not correlated with measured
estradiol concentrations in females (15,16).
Nonetheless, in the absence of direct measurements of
estrogens, a role for estrogen-stimulated increases in NT-
proBNP cannot be excluded. An explanation based purely
on androgen suppressive effects would be inadequate to
account for the known rapid fall in NP concentrations
during the first year of life or the similar levels of NT-
proBNP in male adolescents and male pre-pubertal children
(34). In aggregate, it is likely that both the stimulatory
effects of estrogens and inhibitory effects of testosterone
contribute to the regulation of BNP concentrations during
the life course. The relative concentrations of these sex
hormones may also be an important factor. Additional
population-based studies including pre- and post-pubertal
individuals of both sexes are warranted.
Circulating NPs and use of hormone therapies. Previous
studies examining the impact of HRT on BNP in post-
menopausal women have produced conflicting results
(6,8–10), and none have examined the impact of HC on
circulating BNP in pre-menopausal women. Our study
indicates that usage of HC in pre-menopausal women is
associated with higher circulating NT-proBNP levels com-
pared with no usage. This may be due to direct stimulatory
effects of estrogens on the NP system, a reduction in
FT-mediated suppression of NT-proBNP secondary to
increased SHBG from oral estrogens, or indirect effects of
oral estrogens and progestins acting via the renin-
angiotensin system to modulate NP levels (12). Consistent
with previous studies (8,16), we did not detect a significant
association between naturally occurring menopause and
NT-proBNP concentrations after accounting for age, al-
though the relatively small number of post-menopausal
women in our middle-aged sample may have limited our
statistical power to detect a difference. We were similarly
unable to demonstrate a significant association between
usage of HRT and circulating NT-proBNP, in contrast to
findings from Olmsted County (6). This could be due to
small numbers of HRT users in our current sample because
we included younger women who were recruited following
publication of the Women’s Health Study and the nation-
wide reduction in HRT prescription rates (2,35). Of note,
the effects of exogenous female sex hormone therapies are
known to vary with the route of administration (36),
formulation (37), and composition; for example, progesto-
gens in HC may exert both androgenic and antiandrogenic
effects (38). These details were not available in our study but
represent important areas for future study.
Study strengths and limitations. Strengths of this study
include the large sample size, community-based design,
careful recording of menstrual history, standardized exam-
inations with routine blood collection, and uniform ascer-
tainment of cardiovascular risk factors including IR. Mea-
surements of estrogens and details regarding the individualhormone components of HC were not available. The
accurate detection of an ovulatory cycle or hormonal
changes in reproductive aging in women requires specific
measurements of female sex hormones and gonadotropins.
A role for estrogen-stimulated increases in circulating BNP
cannot be excluded based on these data. FT was not directly
measured, but estimated FT concentrations from total
testosterone (by mass spectrometry) and SHBG (by radio-
immunoassay) correlate well with direct measurements by
equilibrium dialysis (39–42). Biologically active atrial NP
(43) and BNP (44) provide physiologically meaningful
information but are less practical for measurement in large,
ambulatory cohorts composed of predominantly healthy
individuals, in part because of the high proportion of values
censored by the detection limit of the mature NP assays
(4,5). We acknowledge the potential for residual confound-
ing by unmeasured comorbidities and their pharmacological
therapies, as well as the limited ability to draw conclusions
regarding causality from these observational data. Nonethe-
less, our findings are consistent with experimental data on
the effects of testosterone on NPs.
Conclusions
Circulating NT-proBNP levels were related to sex and
exogenous hormone therapy in men and women from the
general community. Suppression of NPs by androgens may
account for sex- and hormone-related differences in NT-
proBNP concentrations. Given the known cardioprotective
effects of BNP (45), further studies are warranted to
elucidate how these mechanisms may contribute to the
well-described sex-related differences in cardiovascular risk.
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